Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
<p>Abstract</p> <p>Objective</p> <p>To evaluate the impact of adalimumab on health-related quality of life (HRQOL) for patients with moderate to severe plaque psoriasis.</p> <p>Background</p> <p>Psoriasis is a chronic, inflammatory, immune-mediated disease that has a significant impact on patients'...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2008-10-01
|
| Col·lecció: | Health and Quality of Life Outcomes |
| Accés en línia: | http://www.hqlo.com/content/6/1/75 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|